Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.74 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.64 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.61 |
| ▸ | LMNA | P02545 | 3/20 | 0.59 |
| ▸ | MAPT | P10636 | 3/20 | 0.59 |
| ▸ | RAB9A | P51151 | 3/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | NPC1 | O15118 | 2/20 | 0.56 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
| ▸ | GLA | P06280 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5598741 | 1.00 | HCAR2 (0.74) | HCAR2SMN1; SMN2ALDH1A1ABCG2LMNA | |
| SCHEMBL12425740 | 0.91 | HCAR2 (0.62) | HCAR2SMN1; SMN2ALDH1A1ABCG2LMNA | |
| SCHEMBL9329482 | 0.89 | HCAR2 (0.66) | HCAR2SMN1; SMN2ALDH1A1ABCG2LMNA | |
| SCHEMBL9329490 | 0.89 | HCAR2 (0.66) | HCAR2SMN1; SMN2ALDH1A1ABCG2LMNA | |
| SCHEMBL29242546 | 0.88 | HCAR2 (0.65) | HCAR2SMN1; SMN2ALDH1A1ABCG2LMNA | |
| SCHEMBL28357180 | 0.86 | ABCG2 (0.65) | HCAR2SMN1; SMN2ALDH1A1ABCG2LMNA | |
| SCHEMBL1086015 | 0.85 | HCAR2 (0.71) | HCAR2SMN1; SMN2ALDH1A1ABCG2LMNA | |
| SCHEMBL143282 | 0.85 | HCAR2 (1.00) | HCAR2SMN1; SMN2ALDH1A1ABCG2LMNA | |
| SCHEMBL4197243 | 0.85 | HCAR2 (0.71) | HCAR2SMN1; SMN2ALDH1A1ABCG2LMNA | |
| SCHEMBL600082 | 0.85 | HCAR2 (1.00) | HCAR2SMN1; SMN2ALDH1A1ABCG2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117986921-A | High-speed printing UV ink | 珠海天威新材料股份有限公司 | 2024-05-07 | — | — | CN | claimed |
| CN-117986921-A | High-speed printing UV ink | 珠海天威新材料股份有限公司 | 2024-05-07 | — | — | CN | disclosed |
| US-20160039734-A1 | THERAPEUTIC CURCUMIN DERIVATIVES | STC UNM (US) | 2016-02-11 | — | — | US | disclosed |
| US-9187397-B2 | Therapeutic curcumin derivatives | STC.UNM (US) | 2015-11-17 | — | — | US | disclosed |
| US-20150011494-A1 | THERAPEUTIC CURCUMIN DERIVATIVES | STC.UNM | 2015-01-08 | — | — | US | disclosed |
| US-8841326-B2 | Therapeutic curcumin derivatives | STC.UNM (US) | 2014-09-23 | — | — | US | disclosed |
| US-20070060644-A1 | Therapeutic curcumin derivatives | STC.UNM | 2007-03-15 | — | — | US | disclosed |
| US-20060276536-A1 | Cancer treatment using curcumin derivatives | STC.UNM | 2006-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160039734-A1 | THERAPEUTIC CURCUMIN DERIVATIVES | FABP2, GLS2, FABP1 | HCAR2 414/4885SMN1; SMN2 88/4885ALDH1A1 670/4885 |
| US-20070060644-A1 | Therapeutic curcumin derivatives | FABP2, GLS2, FABP1 | HCAR2 414/4885SMN1; SMN2 88/4885ALDH1A1 670/4885 |
| US-20150011494-A1 | THERAPEUTIC CURCUMIN DERIVATIVES | FABP2, GLS2, FABP1 | HCAR2 414/4885SMN1; SMN2 88/4885ALDH1A1 670/4885 |
| US-20060276536-A1 | Cancer treatment using curcumin derivatives | BRCA1, VHL, TP53 | HCAR2 679/4885SMN1; SMN2 3797/4885ALDH1A1 110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.